Drug Profile
Research programme: osteoporosis therapy - Ferring/Beth Israel Deaconess Medical Center
Latest Information Update: 12 Dec 2007
Price :
$50
*
At a glance
- Originator Beth Israel Deaconess Medical Center; Ferring Pharmaceuticals
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 16 Mar 2007 No development reported - Preclinical for Postmenopausal osteoporosis treatment in USA (unspecified route)
- 31 Oct 2002 Preclinical trials in Postmenopausal osteoporosis treatment in USA (unspecified route)